Tandem Diabetes Care Narrows Losses on 6% Sales Growth, Gross Margin Hits 57%
TNDM sits 75% above its 52-week low of $9.98.
Summary
Tandem Diabetes Care reported Q2 2026 sales of $254.6 million, a 6% increase, with gross margin improving to 57%. Net loss narrowed to $21.2 million. The company invested an additional $81.4 million in CeQur SA and submitted a 510(k) for a tubeless Mobi pump.
Key Events · Earnings and Guidance · TNDM
-
Q2 Sales Rise 6% to $254.6M
Revenue increased to $254.6 million from $240.7 million a year ago, driven by higher pump volumes and favorable pharmacy channel mix. U.S. sales grew 5% to $179.3 million; international sales rose 7% to $75.3 million.
-
Gross Margin Expands to 57%
Gross profit jumped to $144.8 million, with gross margin improving to 57% from 52%, reflecting better pricing from pharmacy and direct international sales, plus manufacturing efficiencies.
-
Net Loss Narrows to $21.2M
Net loss was $21.2 million ($0.31 per share) versus $52.4 million a year ago, benefiting from the absence of $20.0 million in litigation settlement and $75.2 million in IPR&D charges incurred in Q2 2025.
-
$81.4M Additional Investment in CeQur SA
On May 22, 2026, Tandem invested an additional CHF 64.0 million ($81.4 million) in CeQur SA, increasing its equity method investment to $132.3 million. The company also obtained an option to acquire the remainder of CeQur no earlier than 2028.
Analysis · TNDM · Industrial Applications And Services
Tandem's Q2 results mark a meaningful step toward profitability. Sales climbed 6% to $254.6 million, fueled by a favorable shift to the pharmacy channel and higher pump volumes. Gross margin expanded to 57% from 52% a year ago, reflecting better pricing and manufacturing efficiencies. The net loss shrank to $21.2 million from $52.4 million, helped by the absence of last year's one-time litigation and IPR&D charges. The company also invested an additional $81.4 million in CeQur SA, deepening its bet on a complementary insulin delivery technology, and submitted a 510(k) for a tubeless Mobi option—a key pipeline milestone. With $456 million in cash and investments, the balance sheet remains solid, but the path to sustained profitability still depends on scaling the pharmacy model and resolving supply constraints.
At the time of this filing, TNDM was trading at $17.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.98 to $29.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.